Innovent Biologics, Inc. reported revenue results for the first quarter of 2024. for the quarter, the Company achieved a total product revenue exceeding RMB 1.7 billion, representing a robust year-over-year growth of over 60%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.8 HKD | +0.14% | +1.70% | -16.26% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.26% | 7.46B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
+64.77% | 26.66B | |
-13.54% | 15.32B | |
-5.97% | 13.3B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B | |
+2.32% | 9.06B |
- Stock Market
- Equities
- 1801 Stock
- News Innovent Biologics, Inc.
- Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024